组织型纤溶酶原激活剂治疗COVID-19相关ARDS:病例系列
本文报告3例重症COVID-19呼吸衰竭患者接受组织型纤溶酶原激活剂(tPA)治疗。所有患者呼吸状态均出现时间相关改善,其中1例为持久反应。背景认为COVID-19呼吸衰竭可能由肺微血栓导致的血管闭塞所致,而非典型ARDS低顺应性。
要点
- 重症COVID-19 ARDS患者常见促血栓性凝血病,尸检示弥漫性肺微血栓。
- 3例接受tPA治疗者呼吸状态均时间相关改善,1例持久反应。
- 既往纤溶治疗1期试验曾显示降低死亡率和改善氧合。
核心结论
- tPA治疗3例重症COVID-19呼吸衰竭患者后,所有患者呼吸状态出现时间相关改善,其中1例为持久反应。
研究设计与样本
- 病例系列,报告3例重症COVID-19呼吸衰竭接受tPA治疗的患者。
主要发现
- 所有3例患者呼吸状态出现时间相关改善,其中1例为持久反应。
局限性
- 病例系列样本量小(3例),无对照,无法确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A prothrombotic coagulopathy is commonly found in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). A unique feature of COVID-19 respiratory failure is a relatively preserved lung compliance and high Alveolar-arterial oxygen gradient, with pathology reports consistently demonstrating diffuse pulmonary microthrombi on autopsy, all consistent with a vascular occlusive etiology of respiratory failure rather than the more classic findings of low-compliance in ARDS. The COVID-19 pandemic is overwhelming the world's medical care capacity with unprecedented needs for mechanical ventilators and high rates of mortality once patients progress to needing mechanical ventilation, and in many environments including in parts of the United States the medical capacity is being exhausted. Fibrinolytic therapy has previously been used in a Phase 1 clinical trial that led to reduced mortality and marked improvements in oxygenation. Here we report a series of three patients with severe COVID-19 respiratory failure who were treated with tissue plasminogen activator. All three patients had a temporally related improvement in their respiratory status, with one of them being a durable response.
引用
- Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost. 2020. PMID: 32267998. doi:10.1111/jth.14828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。